久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

BeiGene's cancer therapy gets green light

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-04-12 18:32
Share
Share - WeChat
Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn]

China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.

The NMPA approval is based on the clinical results from a single-arm, multi-center pivotal Phase 2 trial of tislelizumab in patients in China and South Korea.

Among patients who were evaluable for response, with a minimum follow-up of 12 months and a median follow-up of 14 months, the objective response rate (ORR) as assessed by the independent review committee was 24.8 percent, and the complete response (CR) rate was 9.9 percent.

The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.

According to Ye Dingwei, vice-president of Fudan University Shanghai Cancer Center, patients with advanced UC have limited treatment options, and it is great that tislelizumab, a new immuno-oncology treatment, becomes available to them.

Supported by encouraging efficacy and safety results from the trial, tislelizumab is believed to bring significant benefits to the patients, he said.

The company also has a broad development program for tislelizumab that encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkin's lymphoma and UC.

"This is our third new drug application approval in the past five months for our internally developed products, a tremendous accomplishment for a young biotechnology company like BeiGene and validation of the team's hard work," said John V. Oyler, the company's chairman, co-founder, and CEO.

"Our strategy for tislelizumab has always been to pursue a broad label and serve patients who are battling different types of cancer. With tislelizumab's first solid tumor approval, we are even more excited about the outlook for this immunotherapy than ever."

However, like other immune checkpoint inhibitors, tislelizumab could cause immune-related adverse reactions that mainly include pneumonitis, diarrhea and colitis, hepatitis, and endocrinopathies (hypothyroidism, hyperthyroidism and thyroiditis, adrenocortical insufficiency, hyperglycemia and type 1 diabetes mellitus), and skin adverse reactions. Occasionally, nephritis, pancreatitis, myocarditis, myositis, and other immune-related adverse reactions were also reported, the company said in a release.

Most common adverse reactions included rash, fatigue, and increased alanine aminotransferase.

The recommended dose of tislelizumab is 200 mg administered as an intravenous infusion every three weeks until disease progression or intolerable toxicity.

Tislelizumab is not approved for use outside China.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲欧美日韩国产精品 | 欧美中日韩在线 | 午夜三级成人三级 | 国产成人精品视频在放 | 萌白酱喷水福利视频在线 | 韩日一级毛片 | 亚洲一区在线观看视频 | 久草热视频 | 黄网在线免费 | 国产一级视频在线观看 | 欧美在线观看视频一区 | 亚洲精品一区二区手机在线 | 欧美.亚洲.日本一区二区三区 | 国产日韩精品视频一区二区三区 | www.黄色片| 亚洲第一成年免费网站 | 久久精品视频日本 | 欧美巨大精品欧美一区二区 | 久久亚洲不卡一区二区 | 一级毛片子 | 可以免费看黄的网址 | 岛国在线永久免费视频 | 久久成人免费观看全部免费 | 亚洲tv成人天堂在线播放 | 亚洲天堂美女视频 | 欧美人成在线视频 | 暖暖免费高清日本一区二区三区 | 免费日本在线视频 | 欧美一级毛片免费看高清 | 久久成人精品免费播放 | 亚洲成年人免费网站 | 日韩特级 | 欧美日本韩国一区二区 | 国产精品视频久久久久久 | 18在线| 日韩在线视频网址 | 操操综合 | 欧美成人午夜视频免看 | 免费刺激视频 | 亚洲好视频 | 欧美日韩国产片 |